✨ Medicines Act Notices




NEW ZEALAND GAZETTE

No. 4


Health

Medicines Act 1981

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Sodium chloride 4 mmol/mL in 20 mL Injection, ampoule McGaw Biomed Limited, Point Chevalier, Auckland
Isosorbide mononitrate 60 mg Tablet, film coated Euderma Srl., Superstrada Rimini, Italy and Valpharma SA., Serravalle, Republica di San Marino Imtrate
Cisatracurium besylate 2 mg/mL in 2.5 mL, 5 mL, 10 mL, 25 mL Injection, ampoule Wellcome Foundation Limited, Dartford, Kent, United Kingdom Nimbex
Cisatracurium besylate 5 mg/mL in 30 mL Injection, vial Wellcome Foundation Limited, Dartford, Kent, United Kingdom Nimbex
Reteplase 10U and diluent Powder for injection, vial Diluent, pre-filled syringe Boehringer Mannheim GmbH., Mannheim, Germany Rapilysin 10 U
Fexofenadine hydrochloride 60 mg Capsule Marion Merrell Dow Inc., Kansas City, Missouri, United States of America Telfast
Remifentanil hydrochloride equivalent to 1 mg, 2 mg, 5 mg remifentanil base Powder for injection, vial Pharmacia & Upjohn nv/sa., Puurs, Belgium Ultiva

Dated this 6th day of January 1997.

KAREN O. POUTASSI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.

god419


Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Ibuprofen 100 mg/5 mL in 50 mL, 100 mL, 200 mL Suspension, oral Whitehall-Robins, Richmond, Virginia, United States of America and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Act-3
Alteplase (plasminogen activator) 10 mg, 20 mg, 50 mg and diluent Injection, powder, glass vial; diluent, ampoule Dr Karl Thomae GmbH., Biberach, Biberach an der Riss, Germany Actilyse
Ipratropium bromide monohydrate 0.52 mg equivalent to 0.5 mg ipratropium bromide, salbutamol sulphate 3.01 mg equivalent to 2.5 mg salbutamol in 2.5 mL Solution, inhaled Boehringer Ingelheim Limited, Bracknell, Berkshire, England Combivent Respules
Etoposide phosphate 113.6 mg equivalent to 100 mg etoposide Injection, powder, glass vial Bristol-Caribbean Inc., Mayaguez, Puerto Rico Etopophos
Cetylpyridinium chloride 1.5 mg Lozenge Barratts Pharmaceuticals Pty Limited, Blacktown, New South Wales, Australia Lemsip
Cisapride 5 mg, 10 mg Tablets Janssen Pharmaceutic nv., Beerse, Belgium Prepulsid, Prepulsid Forte


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1997, No 4


NZLII PDF NZ Gazette 1997, No 4





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
6 January 1997
Medicines Act 1981, New Medicines, Distribution Consent
  • KAREN O. POUTASSI (Dr), Director-General of Health

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
Medicines Act 1981, Changed Medicines, Distribution Consent